

**TOXICOLOGICAL PROFILE FOR
PENTACHLOROPHENOL**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry**

September 2001

DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

UPDATE STATEMENT

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology/Toxicology Information Branch
1600 Clifton Road NE, E-29
Atlanta, Georgia 30333

FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.


The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.


 Jeffrey P. Koplan, M.D., M.P.H.
 Administrator
 Agency for Toxic Substances and
 Disease Registry

*Legislative Background

The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed ATSDR to prepared toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. The availability of the revised priority list of 275 hazardous substances was announced in the *Federal Register* on November 17, 1997 (62 FR 61332). For prior versions of the list of substances, see *Federal Register* notices dated April 29, 1996 (61 FR 18744); April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); and February 28, 1994 (59 FR 9486). Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list.

QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance's relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, and assesses the significance of toxicity data to human health.

Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by *type of health effect* (death, systemic, immunologic, reproductive), by *route of exposure*, and by *length of exposure* (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

Pediatrics: Four new sections have been added to each Toxicological Profile to address child health issues:

Section 1.6	How Can (Chemical X) Affect Children?
Section 1.7	How Can Families Reduce the Risk of Exposure to (Chemical X)?
Section 3.7	Children's Susceptibility
Section 6.6	Exposures of Children

Other Sections of Interest:

Section 3.8	Biomarkers of Exposure and Effect
Section 3.11	Methods for Reducing Toxic Effects

ATSDR Information Center

Phone: 1-888-42-ATSDR or 404-498-0110 **Fax:** 404-498-0057
E-mail: atsdric@cdc.gov **Internet:** <http://www.atsdr.cdc.gov>

The following additional material can be ordered through the ATSDR Information Center:

Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure history is provided. Other case studies of interest include *Reproductive and Developmental Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide Toxicity*; and numerous chemical-specific case studies.

Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. *Contact:* NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. *Contact:* NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. *Contact:* NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

Referrals

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. *Contact:* AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: <http://www.aoec.org/>.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. *Contact:* ACOEM, 55 West Seegers Road, Arlington Heights, IL 60005 • Phone: 847-818-1800 • FAX: 847-818-9266.

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHORS(S):

Lori L. Miller, M.P.H.
ATSDR, Division of Toxicology, Atlanta, GA

Lisa D. Ingerman, Ph.D.
Mona Singh, Ph.D.
Syracuse Research Corporation, North Syracuse, NY

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Research Implementation Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.

PEER REVIEW

A peer review panel was assembled for pentachlorophenol. The panel consisted of the following members:

1. Dr. Donald Morgan, Professor Emeritus in Preventive Medicine, University of Iowa Medical School, 1650 Koehler Drive NW, #247, Cedar Rapids, IA 52405;
2. Dr. Norman Rawlings, Professor of Veterinary Physiological Sciences, Department of Veterinary Biomedical Sciences, University of Saskatchewan, 52 Campus Drive, Saskatoon, SK S7N 5B4 Canada;
3. Dr. Thomas Thompson, Manager of Environmental Sciences, Saskatchewan Health Provincial Laboratory, 3211 Albert Street, Regina, SK S4S 5W6 Canada;
4. Dr. Loren Koller, Professor, College of Veterinary Medicine, Oregon State University, 105 Magruder Hall, Corvallis, OR 97331-4802;
5. Dr. Philip Leber, Goodyear Tire & Rubber Company, 1485 East Archwood Avenue, Akron, OH 44306;
6. Dr. John Lech, Professor, Pharmacology and Toxicology, Medical College of Wisconsin, 8701 Watertown Park Road, Milwaukee, WI 53226; and
7. Dr. Frederick Oehme, Professor, Comparative Toxicology Laboratories, 1800 Denison Avenue, Kansas State University, Manhattan, KS 66506-5606.

These experts collectively have knowledge of pentachlorophenol's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

CONTENTS

FOREWORD	v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS	vii
CONTRIBUTORS	ix
PEER REVIEW	xi
LIST OF FIGURES	xvii
LIST OF TABLES	xix
1. PUBLIC HEALTH STATEMENT	1
1.1 WHAT IS PENTACHLOROPHENOL?	1
1.2 WHAT HAPPENS TO PENTACHLOROPHENOL WHEN IT ENTERS THE ENVIRONMENT?	2
1.3 HOW MIGHT I BE EXPOSED TO PENTACHLOROPHENOL?	3
1.4 HOW CAN PENTACHLOROPHENOL ENTER AND LEAVE MY BODY?	4
1.5 HOW CAN PENTACHLOROPHENOL AFFECT MY HEALTH?	4
1.6 HOW CAN PENTACHLOROPHENOL AFFECT CHILDREN?	6
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO PENTACHLOROPHENOL?	7
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO PENTACHLOROPHENOL?	9
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?	9
1.10 WHERE CAN I GET MORE INFORMATION?	11
2. RELEVANCE TO PUBLIC HEALTH	13
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO PENTACHLOROPHENOL IN THE UNITED STATES	13
2.2 SUMMARY OF HEALTH EFFECTS	14
2.3 MINIMAL RISK LEVELS	17
3. HEALTH EFFECTS	21
3.1 INTRODUCTION	21
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE	21
3.2.1 Inhalation Exposure	23
3.2.1.1 Death	23
3.2.1.2 Systemic Effects	24
3.2.1.3 Immunological and Lymphoreticular Effects	26
3.2.1.4 Neurological Effects	27
3.2.1.5 Reproductive Effects	28
3.2.1.6 Developmental Effects	29
3.2.1.7 Cancer	29
3.2.2 Oral Exposure	31

	3.2.2.1	Death	31
	3.2.2.2	Systemic Effects	32
	3.2.2.3	Immunological and Lymphoreticular Effects	57
	3.2.2.4	Neurological Effects	60
	3.2.2.5	Reproductive Effects	62
	3.2.2.6	Developmental Effects	63
	3.2.2.7	Cancer	65
	3.2.3	Dermal Exposure	68
	3.2.3.1	Death	68
	3.2.3.2	Systemic Effects	70
	3.2.3.3	Immunological and Lymphoreticular Effects	73
	3.2.3.4	Neurological Effects	73
	3.2.3.5	Reproductive Effects	73
	3.2.3.6	Developmental Effects	74
	3.2.3.7	Cancer	74
	3.2.4	Other Routes of Exposure	74
3.3		GENOTOXIC EFFECTS	75
3.4		TOXICOKINETICS	80
	3.4.1	Absorption	81
	3.4.1.1	Inhalation Exposure	81
	3.4.1.2	Oral Exposure	82
	3.4.1.3	Dermal Exposure	83
	3.4.2	Distribution	84
	3.4.2.1	Inhalation Exposure	85
	3.4.2.2	Oral Exposure	86
	3.4.2.3	Dermal Exposure	87
	3.4.2.4	Other Routes of Exposure	88
	3.4.3	Metabolism	89
	3.4.3.1	Inhalation Exposure	91
	3.4.3.2	Oral Exposure	91
	3.4.3.3	Dermal Exposure	93
	3.4.3.4	Other Routes of Exposure	93
	3.4.4	Elimination and Excretion	94
	3.4.4.1	Inhalation Exposure	94
	3.4.4.2	Oral Exposure	96
	3.4.4.3	Dermal Exposure	98
	3.4.4.4	Other Routes of Exposure	99
	3.4.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	100
3.5		MECHANISMS OF ACTION	101
	3.5.1	Pharmacokinetic Mechanisms	101
	3.5.2	Mechanisms of Toxicity	103
	3.5.3	Animal-to-Human Extrapolations	106
3.6		ENDOCRINE DISRUPTION	106
3.7		CHILDREN'S SUSCEPTIBILITY	108
3.8		BIOMARKERS OF EXPOSURE AND EFFECT	111
	3.8.1	Biomarkers Used to Identify or Quantify Exposure to Pentachlorophenol	112
	3.8.2	Biomarkers Used to Characterize Effects Caused by Pentachlorophenol	114
3.9		INTERACTIONS WITH OTHER CHEMICALS	115
3.10		POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	116
3.11		METHODS FOR REDUCING TOXIC EFFECTS	118

3.11.1	Reducing Peak Absorption Following Exposure	118
3.11.2	Reducing Body Burden	119
3.11.3	Interfering with the Mechanism of Action for Toxic Effects	119
3.12	ADEQUACY OF THE DATABASE	119
3.12.1	Existing Information on Health Effects of Pentachlorophenol	120
3.12.2	Identification of Data Needs	122
3.12.3	Ongoing Studies	135
4.	CHEMICAL AND PHYSICAL INFORMATION	137
4.1	CHEMICAL IDENTITY	137
4.2	PHYSICAL AND CHEMICAL PROPERTIES	137
5.	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	141
5.1	PRODUCTION	141
5.2	IMPORT/EXPORT	141
5.3	USE	141
5.4	DISPOSAL	143
6.	POTENTIAL FOR HUMAN EXPOSURE	145
6.1	OVERVIEW	145
6.2	RELEASES TO THE ENVIRONMENT	147
6.2.1	Air	147
6.2.2	Water	151
6.2.3	Soil	151
6.3	ENVIRONMENTAL FATE	152
6.3.1	Transport and Partitioning	153
6.3.2	Transformation and Degradation	156
6.3.2.1	Air	156
6.3.2.2	Water	157
6.3.2.3	Sediment and Soil	159
6.3.2.4	Other Media	161
6.4	LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	162
6.4.1	Air	162
6.4.2	Water	162
6.4.3	Sediment and Soil	163
6.4.4	Other Environmental Media	164
6.5	GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	165
6.6	EXPOSURES OF CHILDREN	172
6.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	176
6.8	ADEQUACY OF THE DATABASE	176
6.8.1	Identification of Data Needs	177
6.8.2	Ongoing Studies	182
7.	ANALYTICAL METHODS	185
7.1	BIOLOGICAL MATERIALS	185
7.2	ENVIRONMENTAL SAMPLES	187
7.3	ADEQUACY OF THE DATABASE	193
7.3.1	Identification of Data Needs	198
7.3.2	Ongoing Studies	199
8.	REGULATIONS AND ADVISORIES	201

9. REFERENCES	213
---------------------	-----

10. GLOSSARY	263
--------------------	-----

APPENDICES

A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS	A-1
---	-----

B. USER'S GUIDE	B-1
-----------------------	-----

C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS	C-1
---	-----

D. INDEX	D-1
----------------	-----

LIST OF FIGURES

3-1. Levels of Significant Exposure to Pentachlorophenol - Oral	47
3-2. Proposed Metabolic Scheme for Pentachlorophenol	90
3-3. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance	102
3-4. Existing Information on Health Effects of Pentachlorophenol	121
6-1. Frequency of NPL Sites with Pentachlorophenol Contamination	146

LIST OF TABLES

3-1. Levels of Significant Exposure to Pentachlorophenol - Oral	33
3-2. Results of Analyses of Impurities Present in the Pentachlorophenol Used in National Toxicology Program (NTP) Feeding Studies and the Types of Tumors They Induce	51
3-3. Genotoxicity of Pentachlorophenol <i>In Vivo</i>	76
3-4. Genotoxicity of Pentachlorophenol and its Metabolites <i>In Vitro</i>	77
4-1. Chemical Identity of Pentachlorophenol and Pentachlorophenate	138
4-2. Physical and Chemical Properties of Pentachlorophenol and Sodium Pentachlorophenate	139
5-1. Facilities that Produce, Process, or Use Pentachlorophenol	142
6-1. Releases to the Environment from Facilities that Produce, Process, or Use Pentachlorophenol	149
7-1. Analytical Methods for Determining Pentachlorophenol and Metabolites in Biological Samples	188
7-2. Analytical Methods for Determining Pentachlorophenol and Metabolites in Environmental Samples	194
8-1. Regulations and Guidelines Applicable to Pentachlorophenol	203